News Releases

News Releases

Year None20202019

Sep 04, 2020

Immunovant Announces Closing of $200.0 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Sep 02, 2020

Immunovant Announces Pricing of Public Offering

Aug 25, 2020

Immunovant Announces Positive Topline Results from Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis

Aug 24, 2020

Immunovant Appoints Michael Elliott Chief Scientific Officer

Aug 12, 2020

Immunovant Reports Financial Results for the Quarter Ended June 30, 2020

Jun 29, 2020

Immunovant Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2020 and Announces Plans for Phase 3 Registrational Trial of IMVT-1401 in Myasthenia Gravis

May 14, 2020

Immunovant Announces Redemption of Warrants and Achievement of First Earnout Milestone under Share Exchange Agreement

Apr 16, 2020

Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apr 14, 2020

Immunovant Announces Pricing of $121.2 Million Public Offering

Mar 30, 2020

Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease

Displaying 1 - 10 of 12